University of Iowa Hospitals and Clinics

Clinical Trial Details

Short Title
Official Title
A Phase 2, Multicenter, Single-Arm Study to Evaluate the Efficacy and Safety of Single-Agent Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Subjects with Mantle Cell Lymphoma Who Progress after Bortezomib Therapy, MCL-2001
Description

Participants in this study have been diagnosed with Mantle Cell Lymphoma (MCL), which has been previously treated and the disease has returned. The purpose of the study is to assess the effects (both good and bad) of Ibrutinib in MCL and whether the MCL responds to treatment. The Study treatment is a maximum of 3 years, depending on how well the participant responds to treatment.

Start Date
January 10, 2013
End Date
January 10, 2023
Gender Preference
None
Age Group
18 - 99 years
Principal Investigator
Lori Rosenstein, MD
Contact Info

Mary Schall 319-356-3516

Department
Keywords
cancer ; Ibrutinib ; IRB#201207512 ; Mantle Cell Lymphoma (MCL) ; MCL-2001 ; phase II ; phase two ; rosenstein ;

We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.